Relay Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Relay Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q2 2024.
  • Relay Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$92.2M, a 6.39% increase year-over-year.
  • Relay Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$323M, a 6.27% increase year-over-year.
  • Relay Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$342M, a 17.7% decline from 2022.
  • Relay Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$291M, a 20.2% increase from 2021.
  • Relay Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$364M, a 594% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$323M -$92.2M +$6.29M +6.39% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$329M -$81.4M +$12.9M +13.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-06
Q4 2023 -$342M -$83.5M -$16M -23.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 -$326M -$65.7M +$18.4M +21.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$344M -$98.5M -$21.7M -28.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$323M -$94.2M -$32.2M -51.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-06
Q4 2022 -$291M -$67.5M -$47K -0.07% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 -$290M -$84.2M -$23.3M -38.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$267M -$76.8M +$117M +60.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-02
Q1 2022 -$384M -$62M -$19.9M -47.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-02
Q4 2021 -$364M -$67.5M -$103M -291% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 -$261M -$60.8M -$24.8M -68.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$236M -$193M -$167M -624% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$69.7M -$42.2M -$17.3M -69.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$52.4M $35.3M +$59.2M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 -$112M -$36.1M -$16.4M -83.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$95.2M -$26.7M -$9.19M -52.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$86M -$24.9M -$10.7M -75.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$75.3M -$23.9M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 -$19.7M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$17.5M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$14.2M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.